Microbix Biosystems has introduced the new Omicron variant swab-formatted test control, expanding its portfolio of quality assessment products (QAPs).
The new test control helps to validate the integrity and accuracy of nucleic-acid based tests’ workflows for the SARS-CoV-2 Wuhan strain and Omicron variant.
The company is commercialising its in-vitro diagnostic (IVD) quality controls that can help to improve the workflow accuracy of clinical laboratory PCR tests, which aim to identify and differentiate the Wuhan strain and Omicron variant of SARS-CoV-2.
The Omicron QAP is developed using COPAN FLOQSwabs and is labelled as REDx FLOQ SARS-CoV-2 B.1.1.529 Swab Positive Control.
It offers a comprehensive and cost-effective quality management tool that helps avoid systemic errors made by consumables, technicians or instruments.
Microbix Biosystems CEO and president Cameron Groome said: “For optimal patient care and public health management, clinicians and lab directors need controls that can provide them justifiable confidence in the accuracy and reliability of their testing programmes.
“Microbix’s suite of QAPs to support testing for respiratory pathogens is providing that essential support, driven by our ability to quickly respond to the emergence of new viruses or variants with pandemic-generating potential.
“We are pleased to add this Omicron-oriented QAP to maintain our complete coverage of all major Covid variants.”
The company stated that the QAP is currently available to support the quality management systems of clinical laboratories, covering central labs, as well as point-of care workflows in Canada and the US.
Last December, Microbix Biosystems introduced the new Multiplex Respiratory PCR-Test Control, which is branded as REDx FLOQ SARS-CoV-2/Flu A&B/RSV Swab Positive Control.